These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16248763)

  • 21. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
    J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical results using biochemotherapy as a standard of care in advanced melanoma.
    Chapman PB; Panageas KS; Williams L; Wolchok JD; Livingston PO; Quinn C; Hwu WJ
    Melanoma Res; 2002 Aug; 12(4):381-7. PubMed ID: 12170188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
    González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
    Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
    Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
    Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
    Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
    Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
    Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
    Kim KB; Sanguino AM; Hodges C; Papadopoulos NE; Eton O; Camacho LH; Broemeling LD; Johnson MM; Ballo MT; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Prieto VG; Bedikian AY
    Cancer; 2004 Apr; 100(7):1478-83. PubMed ID: 15042682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
    Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
    J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
    Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
    Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
    Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.